Table 1

Lung function and healthcare outcomes for cohort

BaselineFollow-upp Value
Pre-bronchodilator FEV1 % predicted (259)66.4±23.772.7±26.8<0.001
Pre-bronchodilator FVC % predicted (242)82.7±20.386.5±21.50.002
Post-bronchodilator FEV1 % predicted (77)79.2±21.577.6±30.70.61
Post-bronchodilator FVC % predicted (72)90.6± 19.886.3± 25.90.08
Rescue oral steroids in previous 12 months (302)4 (2–6)2 (0–4)<0.001
Hospital admissions in previous 12 months (324)0 (0–2)0 (0–1)<0.01
Unscheduled visits in previous 12 months (315)4 (2–6)2 (0–6)<0.05
Inhaled steroid dose, BDP equivalent (327)2000 (1000–2000)2000 (1200–2000)0.80
Average daily SABA use (205)6 (4–9)8 (4–10)0.058
Blood eosinophils (206)0.33 (0.11–0.60)0.20 (0.09–0.43)<0.001
FeNO (112)40 (18–69)89 (77–102)<0.001
Body mass index29.2±6.530.2±6.4<0.001
  • Group data (mean±SD or median (IQR)) for all subjects are presented in column 1 followed by data for individual centres. Comparisons were made using paired samples t tests or Wilcoxon signed rank tests; significance was taken as p<0.05.

  • BDP, beclometasone dipropionate; FeNO, fractional expiratory nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SABA, short-acting β agonist.